The University of Texas M. D. Anderson Cancer Center (MDACC) is a free-standing comprehensive cancer center established within the University of Texas system. The mission of the MDACC is to eliminate cancer in Texas, the nation and the world through outstanding integrated programs of patient care, research, education and prevention. MDACC is dedicated wholly to the study of cancer involving a continuum of basic, clinical and population-based investigation, with an emphasis on multidisciplinary translational research. During the last 5 years, the number of cancer center members has increased 52%, facilities including those under construction have increased 32% and new patients have increased 32%. Publications listed in Pub Med have increased 27% with many articles in journals with the highest impact factors, reflecting substantial contributions to cancer research. Overall, grant funding has increased 80%. During the last 4 years, awarded NCI grant support has increased from $42M to $80M (90%). If present trends continue, NCI support will more than double by the time the CCSG is renewed. Research Programs have been reduced from 28 to 19 with one additional program in development. Criteria for program membership have been revised. The number of Shared Resources has increased from 13 to 20. Shared Resources include facilities for DNA analysis, nucleic acid extraction, sequence analysis, genomics, peptide synthesis, media preparation, research animal support, SCID mice, genetically engineered mice, small animal imaging, tissue procurement and banking, research histopathology, high resolution microscopy, flow cytometry and cellular imaging, pharmacology, human pedigree analysis, biostatistics, bioinformatics, clinical trials support, and protocol review and data monitoring. Funds are also requested for Development, Planning and Evaluation, Administration and for partial support of Senior Leadership and Program Leaders.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016672-32S1
Application #
7489215
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ogunbiyi, Peter
Project Start
1998-09-04
Project End
2008-06-30
Budget Start
2007-08-27
Budget End
2008-06-30
Support Year
32
Fiscal Year
2007
Total Cost
$112,121
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
Other Domestic Higher Education
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Yu, Wangie; Chen, Yunyun; Dubrulle, Julien et al. (2018) Cisplatin generates oxidative stress which is accompanied by rapid shifts in central carbon metabolism. Sci Rep 8:4306
Tanco, Kimberson; Azhar, Ahsan; Rhondali, Wadih et al. (2018) The Effect of Message Content and Clinical Outcome on Patients' Perception of Physician Compassion: A Randomized Controlled Trial. Oncologist 23:375-382
Elimova, Elena; Wang, Xuemei; Qiao, Wei et al. (2018) Actionable Locoregional Relapses after Therapy of Localized Esophageal Cancer: Insights from a Large Cohort. Oncology 94:345-353
Hoadley, Katherine A; Yau, Christina; Hinoue, Toshinori et al. (2018) Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cell 173:291-304.e6
Ma, Jiacheng; Huo, XiaoJiao; Jarpe, Matthew B et al. (2018) Pharmacological inhibition of HDAC6 reverses cognitive impairment and tau pathology as a result of cisplatin treatment. Acta Neuropathol Commun 6:103
Meisel, Jane; Zhang, Chao; Neely, Cameron et al. (2018) Evaluation of Prognosis in Hormone Receptor-Positive/HER2-Negative and Lymph Node-Negative Breast Cancer With Low Oncotype DX Recurrence Score. Clin Breast Cancer 18:347-352
Williams, Patrick; Basu, Sreyashi; Garcia-Manero, Guillermo et al. (2018) The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer :
Koyyalagunta, Dhanalakshmi; Bruera, Eduardo; Engle, Mitchell P et al. (2018) Compliance with Opioid Therapy: Distinguishing Clinical Characteristics and Demographics Among Patients with Cancer Pain. Pain Med 19:1469-1477
Liao, Zhongxing; Lee, J Jack; Komaki, Ritsuko et al. (2018) Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 36:1813-1822
Ma, Junsheng; Hobbs, Brian P; Stingo, Francesco C (2018) Integrating genomic signatures for treatment selection with Bayesian predictive failure time models. Stat Methods Med Res 27:2093-2113

Showing the most recent 10 out of 12418 publications